Adjuvant Durvalumab and the Future of Early-Stage NSCLC
Journal of Clinical Oncology (JCO) Podcast
Release Date: 05/14/2026
Adjuvant Durvalumab and the Future of Early-Stage NSCLC
Journal of Clinical Oncology (JCO) Podcast
Guest Dr. Glenwood Goss discuss JCO article, "" and the implications of minimal residual disease, results regarding the efficacy of immunotherapy in the adjuvant setting, and the evolving strategies for patient care in lung cancer treatment.
info_outline
JCO Article Insights: LEAP-010 Study in Recurrent/Metastatic Head and Neck Cancer
Journal of Clinical Oncology (JCO) Podcast
Host Jake New summarizes and offers insights into the JCO article by Licitra et al., "Pembrolizumab With or Without Lenvatinib as First-Line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Phase III LEAP-010 Study."
info_outline
Infections in Two Diet Strategies in HSCT and Leukemia Patients
Journal of Clinical Oncology (JCO) Podcast
Guest Dr. John Wingard and host Dr. Davide Soldato discuss JCO article, "," the reason behind the trial, its design, methodology, results, and the implications for future dietary approaches in hematology.
info_outline
JCO Article Insights: ctDNA in DLBCL - Ready for Prime Time?
Journal of Clinical Oncology (JCO) Podcast
In this episode of JCO Article Insights, host Dr. Ash Gurumurthi summarizes JCO articles, "" and " " TRANSCRIPT Ash Gurumurthi: Hi and welcome to . I'm your host, Ash Gurumurthi, and today we will be discussing two articles, both published in the , on the real-world utility of circulating tumor DNA (ctDNA) MRD in newly diagnosed large B-cell lymphoma. The first study is the article "" by Dr. Joanna Krupka and colleagues in the United Kingdom. For the sake of convenience, I'll refer to this as the DIRECT study. The second study is "" by Dr. Steven Wang and colleagues in the Netherlands,...
info_outline
The CISTO Study: Radical Cystectomy or Bladder-Sparing Therapy for Recurrent NMIBC
Journal of Clinical Oncology (JCO) Podcast
Guest Dr. John Gore and host Dr. Davide Soldato discuss JCO article, "," which compares radical cystectomy and bladder sparing therapy for patients with recurrent high-grade non-muscle invasive bladder cancer. Dr. Gore and Dr. Soldato focus on the study's patient-centered approach, eligibility criteria, and quality of life after treatment. TRANSCRIPT The disclosures for guests on this podcast can be found in the show notes. Dr. Davide Soldato: Hello and welcome to , the podcast where we sit down with authors from some of the latest articles published in the . I am your host, Dr. Davide...
info_outline
JCO Article Insights: Atezolizumab, Bevacizumab, and Non-Platinum Chemotherapy for PROC
Journal of Clinical Oncology (JCO) Podcast
In this episode of JCO Article Insights, host Dr. Melis Canturk summarizes the article, “” by Harter et al. TRANSCRIPT Melis Canturk: Hello, and welcome to the . I'm your host, Melis Canturk, and today we will be discussing the article, “.” While integrating immune checkpoint inhibitors has revolutionized the treatment of various gynecologic cancers, these agents have historically shown limited single agent activity in ovarian cancer. Despite a strong biological rationale for combining immunotherapy with chemotherapy and bevacizumab to enhance T-cell infiltration and normalized...
info_outline
JCO Article Insights: Ribociclib Plus Letrozole in Recurrent LGSOC: GOG 3026
Journal of Clinical Oncology (JCO) Podcast
In this episode of JCO Article Insights, host Dr. Melis Canturk summarizes the article, "" by Slomovitz et al. TRANSCRIPT Melis Canturk: Hello, and welcome to . I'm your host, Melis Canturk, and today we will be discussing the article, "." Building on the fact that more than 95% of low-grade serous carcinoma are estrogen receptor positive and often exhibit abnormalities in the CDK4/6 signaling pathway, researchers launched the GOG 3026 trial. This study investigated the effectiveness of pairing the CDK4/6 inhibitor ribociclib with letrozole, an aromatase inhibitor, adapting a...
info_outline
NCI Working Group on Biochemically Recurrent Prostate Cancer
Journal of Clinical Oncology (JCO) Podcast
Host Dr. Davide Soldato and guests Dr. David Einstein and Dr. Ravi Madan discuss JCO article, "," underscoring the need for a consensus on clinical trial designs implementing novel endpoints in this population and the importance of PSA doubling time as a prognostic factor, with an emphasis on treatment de-escalation to limit toxicity and improve patient outcomes. TRANSCRIPT The disclosures for guests on this podcast can be found in the show notes. Davide Soldato: Hello and welcome to , the podcast where we sit down with authors from some of the latest articles published in the . I am your...
info_outline
Association Between EOL SACT and Healthcare Utilization
Journal of Clinical Oncology (JCO) Podcast
Host Dr. Davide Soldato and guests Dr. Kerin Adelson and Dr. Maureen Canavan discuss JCO article ",” highlighting adverse outcomes for patients who receive any type of systemic anticancer therapy(SACT) at EOL (end of life) and the need for better communication between oncologists and patients regarding expected risk and benefits of such treatments to properly align goals-of-care. TRANSCRIPT Dr. Davide Soldato: Hello and welcome to , the podcast where we sit down with authors from some of the latest articles published in the . I am your host, , medical oncologist at Ospedale San Martino in...
info_outline
Milan Consensus Endpoints for Bladder Preservation in MIBC
Journal of Clinical Oncology (JCO) Podcast
Guests Dr. Andrea Necchi, Dr. Ashish Kamat and host Dr. Davide Soldato discuss JCO article ",” focusing on the evolving treatment landscape of MIBC (muscle-invasive bladder cancer) and the need to properly design novel trials investigating non-operative management while including the incorporation of biomarkers and patient perspectives in clinical trials. TRANSCRIPT The disclosures for guests on this podcast can be found in the show notes. Dr. Davide Soldato: Hello and welcome to , the podcast where we sit down with authors from some of the latest articles published in the . I am your...
info_outlineGuest Dr. Glenwood Goss discuss JCO article, "Adjuvant Durvalumab in Completely Resected Early-Stage Non-Small Cell Lung Cancer" and the implications of minimal residual disease, results regarding the efficacy of immunotherapy in the adjuvant setting, and the evolving strategies for patient care in lung cancer treatment.